Preclinical data of the novel B7-H3 ADC ICP-B794 was presented at the 2026 AACR, showcasing excellent anti-tumor activity and safety

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (SSE code: 688428; HKEX code: 09969) announced preclinical data for its self-developed novel antibody-drug conjugate (ADC) targeting B7-H3, ICP-B794.

This research achievement was published in poster form at the AACR Annual Meeting (Abstract Code: LB355). ICP-B794 is a novel innovative ADC targeting B7-H3, utilizing innovative linker-payload technology to demonstrate potent anti-tumor activity in preclinical tumor models while offering a significantly wider safety window than similar drugs. A Phase I dose escalation clinical trial is currently underway.

ADCs are hailed as 'biological missiles' for precision tumor targeting. ICP-B794 originates from the company's self-developed ADC technology platform, with core advantages including the use of irreversible linkers paired with highly hydrophilic connectors, as well as the incorporation of a new potent payload. This greatly enhances tumor-killing effects while improving the stability and safety of the ADC drug.

Experimental data shows that ICP-B794 maintains a stable drug-to-antibody ratio (DAR) in human plasma, with payloads less prone to premature release, exhibiting significantly superior in vitro anti-tumor activity compared to similar drugs. Preclinical in vivo efficacy results indicate that ICP-B794’s anti-tumor effect is markedly better than other B7-H3 ADCs, with low-dose administration achieving effective anti-tumor activity. More clinically valuable is the confirmation that ICP-B794 can effectively overcome resistance issues encountered with similar drugs in tumor treatment.

In the safety evaluation, the results of the GLP toxicology study were encouraging, with a safety margin exceeding 200 times.

27K Views